COMPOSITION:
Each tablet contains 50 mg of vildagliptin.
DESCRIPTION:
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults
MECHANISM OF ACTION:
The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion.
By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.
The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.
INDICATIONS:
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults as monotherapy, as dual oral therapy in combination with metformin, sulphonylurea & thiazolidinedione, in combination with insulin and as triple oral therapy in combination with sulphonylurea and metformin
CONTRA-INDICATIONS:
Vildana is contraindicated in patients with known hypersensitivity to vildagliptin or to any of the excipients – Lactose anhydrous, microcrystalline cellulose, sodium starch glycolate, magnesium stearate.
DOSAGE & ADMINISTRATION:
Recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.
When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. Doses higher than 100 mg are not recommended.